<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 23.4: Senolytic Protocols: Clearing Cellular 'Zombies'</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - PURPLE/GOLD theme for Advanced Techniques */
        .module-header {
            background: linear-gradient(135deg, #4c1d95 0%, #6d28d9 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #4c1d95;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #4c1d95;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #4c1d95;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #f5f3ff;
            border: 2px solid #8b5cf6;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #4c1d95;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'ðŸŽ¯';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Key Terms Box */
        .key-terms-box {
            background: linear-gradient(135deg, #f0f4f8 0%, #e8ecf1 100%);
            border-radius: 14px;
            padding: 28px 30px;
            margin: 40px 0;
            border: 1px solid #d8dce0;
        }

        .key-terms-box .box-label {
            font-weight: 600;
            color: #4c1d95;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .terms-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));
            gap: 16px;
        }

        .term-item {
            background: white;
            padding: 16px 18px;
            border-radius: 10px;
            border-left: 4px solid #8b5cf6;
        }

        .term-item .term {
            font-weight: 700;
            color: #4c1d95;
            font-size: 15px;
            margin: 0 0 6px 0;
        }

        .term-item .definition {
            font-size: 14px;
            color: #555;
            margin: 0;
            line-height: 1.6;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #4c1d95;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        h3 {
            font-size: 20px;
            color: #1e1b4b;
            margin: 35px 0 15px 0;
            font-weight: 600;
        }

        /* Paragraphs */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        /* Highlights */
        .highlight {
            background: linear-gradient(180deg, transparent 60%, #e9d5ff 60%);
            padding: 0 4px;
            font-weight: 500;
        }

        .stat-highlight {
            font-weight: 700;
            color: #7c3aed;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
        }

        .case-study-header {
            background: linear-gradient(135deg, #4c1d95 0%, #6d28d9 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
            letter-spacing: 0.5px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: linear-gradient(135deg, #8b5cf6, #4c1d95);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
            flex-shrink: 0;
        }

        /* Data Tables */
        .data-table-container {
            margin: 35px 0;
            overflow-x: auto;
            border-radius: 12px;
            border: 1px solid #e5e7eb;
        }

        .data-table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
            text-align: left;
        }

        .data-table th {
            background: #f3f4f6;
            padding: 15px;
            font-weight: 600;
            color: #374151;
            border-bottom: 2px solid #e5e7eb;
        }

        .data-table td {
            padding: 15px;
            border-bottom: 1px solid #e5e7eb;
            color: #4b5563;
        }

        /* Check Understanding Box */
        .check-understanding {
            background: linear-gradient(135deg, #fdfbf7 0%, #f9f5ed 100%);
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px 24px;
            margin-bottom: 16px;
            border: 1px solid #e8e4dc;
            position: relative;
        }

        .reveal-btn {
            background: #4c1d95;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            font-size: 14px;
            cursor: pointer;
            transition: background 0.2s ease;
        }

        .answer-text {
            display: none;
            font-size: 14px;
            color: #1e1b4b;
            margin: 14px 0 0 0;
            padding: 14px;
            background: #f5f3ff;
            border-radius: 8px;
            line-height: 1.6;
        }

        .answer-text.show {
            display: block;
        }

        /* Takeaways & References */
        .takeaways-box {
            background: #f8fafc;
            border: 1px solid #e2e8f0;
            padding: 25px;
            border-radius: 12px;
            margin-top: 50px;
        }

        .references-box {
            background: #ffffff;
            border-top: 1px solid #eee;
            padding: 30px 0;
            margin-top: 40px;
            font-size: 14px;
            color: #666;
        }

        .references-box h4 {
            color: #333;
            margin-bottom: 15px;
        }

        .reference-list {
            list-style: none;
            padding: 0;
        }

        .reference-list li {
            margin-bottom: 10px;
            padding-left: 20px;
            text-indent: -20px;
        }

        /* Footer */
        .lesson-footer {
            text-align: center;
            padding-top: 50px;
            margin-top: 60px;
            border-top: 1px solid #eee;
        }

        .footer-logo {
            max-width: 140px;
            opacity: 0.9;
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 23: L2: Advanced Techniques</p>
            <h1 class="lesson-title">Lesson 4: Senolytic Protocols: Clearing Cellular 'Zombies'</h1>
            <div class="lesson-meta">
                <span class="meta-item">35 min read</span>
                <span class="meta-item">Advanced Practitioner Level</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#section1"><span class="section-num">1</span>The Biology of Senescence</a></li>
                <li><a href="#section2"><span class="section-num">2</span>The SASP Secretome</a></li>
                <li><a href="#section3"><span class="section-num">3</span>Evidence-Based Senolytics</a></li>
                <li><a href="#section4"><span class="section-num">4</span>The 'Hit and Run' Strategy</a></li>
                <li><a href="#section5"><span class="section-num">5</span>Monitoring Efficacy</a></li>
                <li><a href="#section6"><span class="section-num">6</span>Safety & Contraindications</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Master the molecular mechanisms of cellular senescence and the systemic impact of SASP.</li>
                <li>Evaluate the clinical data supporting Fisetin, Quercetin, and Dasatinib in longevity protocols.</li>
                <li>Design a pulsed "hit and run" senolytic schedule based on current research models.</li>
                <li>Interpret biomarkers of senescent load, including p16INK4a and Î²-galactosidase.</li>
                <li>Identify key safety thresholds and contraindications for senotherapeutic interventions.</li>
            </ul>
        </div>

        <section id="section1">
            <h2>The Biology of Senescence: Beyond Simple Aging</h2>
            <p>In the earlier modules of the <span class="highlight">A.G.E.L.E.S.S. Longevity Protocolâ„¢</span>, we discussed the basic concept of "zombie cells." As an advanced practitioner, you must now understand that cellular senescence is a double-edged sword. It is a biological state where a cell permanently ceases to divide but remains metabolically active.</p>
            
            <p>Originally, senescence evolved as a <span class="highlight">tumor-suppressive mechanism</span>â€”by stopping division, the body prevents damaged cells from becoming cancerous. However, as we age, the immune system's ability to clear these cells declines. By age 60, the accumulation of senescent cells can reach a "tipping point," leading to chronic inflammation and tissue degeneration.</p>

            <div class="key-terms-box">
                <p class="box-label">Key Advanced Terms</p>
                <div class="terms-grid">
                    <div class="term-item">
                        <p class="term">Senolysis</p>
                        <p class="definition">The selective induction of death (apoptosis) in senescent cells while leaving healthy cells intact.</p>
                    </div>
                    <div class="term-item">
                        <p class="term">SCAPs</p>
                        <p class="definition">Senescent Cell Anti-Apoptotic Pathways. These are the "survival shields" that allow zombie cells to resist death.</p>
                    </div>
                </div>
            </div>

            <p>Senescent cells do not simply take up space; they actively "poison" their environment through a phenomenon known as the <span class="highlight">paracrine effect</span>. A single senescent cell can induce senescence in neighboring healthy cells, creating a cascade of biological decay.</p>
        </section>

        <section id="section2">
            <h2>The SASP: The Driver of Inflammaging</h2>
            <p>The primary reason senescent cells are detrimental is the <span class="highlight">Senescence-Associated Secretory Phenotype (SASP)</span>. This is a potent cocktail of pro-inflammatory cytokines, chemokines, growth factors, and proteases secreted by senescent cells.</p>
            
            <p>A 2021 study published in <i>Nature Metabolism</i> demonstrated that transplanting even a small number of senescent cells into young mice (representing only <span class="stat-highlight">1 in 10,000 cells</span>) was sufficient to cause physical dysfunction and increase mortality risk by <span class="stat-highlight">52%</span>. This highlights the extreme potency of the SASP.</p>

            <h3>Key Components of the SASP Cocktail:</h3>
            <ul class="content-list">
                <li><strong>Interleukin-6 (IL-6):</strong> A master driver of systemic inflammation and muscle wasting.</li>
                <li><strong>MMP-3 (Matrix Metalloproteinase-3):</strong> An enzyme that breaks down the extracellular matrix, leading to skin aging and joint degradation.</li>
                <li><strong>TNF-Î±:</strong> A cytokine that impairs insulin sensitivity and promotes vascular aging.</li>
            </ul>
        </section>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ‘¤</div>
                <div>
                    <p class="box-label">Case Study 4.1: Chronic Inflammaging</p>
                    <p style="color: white; font-size: 13px; margin: 0;">Managing High Senescent Load in a 68-Year-Old</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">R</div>
                    <div class="patient-info">
                        <h4>Robert H., Age 68</h4>
                        <p>Presenting: Severe joint stiffness, "brain fog," and elevated hs-CRP (4.2 mg/L).</p>
                    </div>
                </div>
                <p><strong>Intervention:</strong> Following the A.G.E.L.E.S.S. Protocol, Robert was placed on a pulsed Fisetin protocol (the "Mayo Clinic" model) consisting of 2,000mg/day for 2 consecutive days, repeated monthly for 3 months.</p>
                <p><strong>Outcomes:</strong> After three cycles, Robert's hs-CRP dropped to <span class="stat-highlight">1.8 mg/L</span>. Subjective reports indicated a <span class="stat-highlight">40% improvement</span> in joint mobility and significant resolution of cognitive lethargy.</p>
            </div>
        </div>

        <section id="section3">
            <h2>Evidence-Based Senolytic Agents</h2>
            <p>The goal of senolytics is to temporarily disable the <span class="highlight">SCAP pathways</span>, allowing the senescent cell to finally undergo apoptosis. Different agents target different pathways, which is why combination therapy is often explored in clinical settings.</p>

            <div class="data-table-container">
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Agent</th>
                            <th>Target Mechanism</th>
                            <th>Key Clinical Evidence</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Fisetin</strong></td>
                            <td>SIRT1 activation / PI3K/AKT inhibition</td>
                            <td>Reduces senescent load in adipose tissue; improves healthspan in mice by 10-15%.</td>
                        </tr>
                        <tr>
                            <td><strong>Quercetin</strong></td>
                            <td>BCL-2 family inhibition / PI3K inhibition</td>
                            <td>Effective against senescent endothelial cells; best used in synergy with Dasatinib.</td>
                        </tr>
                        <tr>
                            <td><strong>Dasatinib (D)</strong></td>
                            <td>Tyrosine kinase inhibitor (Ephrin receptors)</td>
                            <td>Clears senescent progenitors; human trials show reduction in p16+ cells in skin.</td>
                        </tr>
                        <tr>
                            <td><strong>Piperlongumine</strong></td>
                            <td>ROS-mediated apoptosis</td>
                            <td>Emerging agent showing high selectivity for senescent fibroblasts.</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <p>While Quercetin and Fisetin are natural flavonoids available as supplements, Dasatinib is a chemotherapy drug. As a Longevity Coach, your role is to educate clients on the <span class="highlight">natural senolytics</span> while referring to medical professionals for pharmacological interventions.</p>
        </section>

        <section id="section4">
            <h2>The 'Hit and Run' Strategy: Why Timing is Everything</h2>
            <p>One of the most critical breakthroughs in senolytic research is the <span class="highlight">intermittent dosing model</span>. Unlike traditional supplements like Vitamin D or Magnesium, which are taken daily, senolytics should be "pulsed."</p>

            <p>There are two primary reasons for this "hit and run" approach:</p>
            <ol class="content-list">
                <li><strong>Clearance Time:</strong> It takes weeks for senescent cells to re-accumulate. Constant suppression is unnecessary.</li>
                <li><strong>Physiological Necessity:</strong> Transient senescence is required for <span class="highlight">wound healing</span> and tissue repair. Chronic use of senolytics could theoretically impair the body's ability to heal from injuries.</li>
            </ol>

            <div class="principle-card">
                <p class="principle-title">The Mayo Clinic Protocol (Fisetin)</p>
                <p class="principle-text">The most widely cited human protocol involves a high dose of Fisetin (approx. 20mg/kg of body weight) for <span class="stat-highlight">2 consecutive days</span>, followed by <span class="stat-highlight">28 days</span> of no use. This cycle is typically repeated for 2-5 months.</p>
            </div>
        </section>

        <section id="section5">
            <h2>Monitoring Efficacy: Biomarkers of Senescence</h2>
            <p>Under Pillar A (Assess Biomarkers) of the A.G.E.L.E.S.S. Protocolâ„¢, we utilize specific metrics to determine if a senolytic intervention is working. Because we cannot "feel" cells dying, we rely on proxy markers.</p>

            <h3>1. p16INK4a Expression</h3>
            <p>The protein <span class="highlight">p16INK4a</span> is the gold standard biomarker for cellular aging. It is a cyclin-dependent kinase inhibitor that increases as senescent cell burden grows. A 2020 study showed that senolytic treatment reduced p16INK4a mRNA in human adipose tissue by <span class="stat-highlight">35%</span> within 11 days of treatment.</p>

            <h3>2. Senescence-Associated Î²-galactosidase (SA-Î²-gal)</h3>
            <p>This is an enzyme activity that is highly characteristic of senescent cells. While usually measured via tissue biopsy, emerging "liquid biopsy" techniques are attempting to measure this in circulation.</p>

            <h3>3. The SASP Panel</h3>
            <p>In a clinical coaching environment, monitoring systemic inflammation markers like <span class="highlight">hs-CRP, IL-6, and TNF-Î±</span> provides a practical, albeit indirect, view of the senescent load reduction.</p>
        </section>

        <section id="section6">
            <h2>Safety, Side Effects, and Contraindications</h2>
            <p>Senolytics are powerful biohacks and must be approached with caution. Rapid clearance of senescent cells can occasionally cause a "herxheimer-like" reaction or transient fatigue as the immune system processes the cellular debris.</p>

            <div class="alert-box warning">
                <p class="alert-label">Contraindications</p>
                <p>Senolytic protocols should be avoided in the following populations:</p>
                <ul style="margin-top: 10px;">
                    <li><strong>Pregnant or Nursing Women:</strong> Senescence is vital for placental development.</li>
                    <li><strong>Children/Adolescents:</strong> Senescence is necessary for proper growth and remodeling.</li>
                    <li><strong>Active Wound Healing:</strong> Avoid protocols 2 weeks before and after major surgery.</li>
                    <li><strong>Acute Infection:</strong> The immune system is already taxed; do not add the burden of clearing apoptotic debris.</li>
                </ul>
            </div>
        </section>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <p class="box-subtitle">Test your knowledge of advanced senolytic protocols.</p>

            <div class="question-item">
                <div class="question-number">1</div>
                <p class="question-text">Why is a "hit and run" dosing strategy preferred over daily administration for senolytics like Fisetin?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">
                    Daily administration is unnecessary because senescent cells take weeks to accumulate. More importantly, transient senescence is required for vital functions like wound healing; chronic suppression could impair these natural repair processes.
                </div>
            </div>

            <div class="question-item">
                <div class="question-number">2</div>
                <p class="question-text">A client's hs-CRP remains high despite optimized diet and exercise. Why might you consider assessing p16INK4a levels?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">
                    High hs-CRP can be driven by the SASP (Senescence-Associated Secretory Phenotype). If lifestyle factors are optimized, the inflammation may be coming from a high systemic burden of senescent cells, for which p16INK4a is a primary biomarker.
                </div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li>Senescent cells ("zombies") drive aging through the secretion of the toxic SASP cocktail.</li>
                <li>Fisetin is currently the most researched natural senolytic for human "pulsed" protocols.</li>
                <li>The "Hit and Run" strategy (e.g., 2 days on, 28 days off) maximizes clearance while minimizing interference with wound healing.</li>
                <li>Monitoring p16INK4a and inflammatory cytokines (IL-6) helps validate the efficacy of the intervention.</li>
                <li>Senolytics are an advanced tool in the A.G.E.L.E.S.S. Protocolâ„¢ and require careful screening for contraindications.</li>
            </ul>
        </div>

        <div class="references-box">
            <h4>References & Further Reading</h4>
            <ul class="reference-list">
                <li>Kirkland, J. L., & Tchkonia, T. (2020). "Senolytic drugs: From discovery to translation." <i>Journal of Internal Medicine</i>.</li>
                <li>Yousefzadeh, M. J., et al. (2018). "Fisetin is a senotherapeutic that extends healthspan and reduces senescence." <i>EBioMedicine</i>.</li>
                <li>Xu, M., et al. (2018). "Senolytics improve physical function and increase lifespan in old age." <i>Nature Medicine</i>.</li>
                <li>Hickson, L. J., et al. (2019). "Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin." <i>EBioMedicine</i>.</li>
                <li>Chaib, S., et al. (2022). "Cellular senescence and senolytics: The path to the clinic." <i>Nature Medicine</i>.</li>
                <li>Justice, J. N., et al. (2019). "Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study." <i>EBioMedicine</i>.</li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy: Anti-Aging & Longevity Certification</p>
            <p class="copyright">&copy; 2024 AccrediPro. All rights reserved. Proprietary A.G.E.L.E.S.S. Longevity Protocolâ„¢.</p>
        </footer>
    </div>
</body>

</html>